As the industry is looking to increase speed to market, reduce manufacturing resources and increase product safety, there has been a push to implement single-use technologies. Combining both SPTFF and single-use technology can be a powerful tool for the efficient manufacture of biologics.
This webinar discusses several scaling approaches, such as constant tip speed, kLa, and power number-based scale-up.
This webcast reviews a research example for process development with the human tumor cell line H157, cultivated in stirred-tank mini bioreactors as 3D cell aggregates.
See applications of MVA and DoE in bioprocess development and how these powerful tools can be integrated in this live webcast.
This webinar presents a solution for automated glucose monitoring and feeding during a bioprocess run. Join Dr. Stacey Willard, as she shares insights on streamlining bioprocess development efforts through automation.
This webinar discusses a research project focused on determining if the three primary methods of production for a typical biosimilar (batch, fed-batch, and perfusion) may be simply and easily executed using a single, benchtop bioprocess control system.
This presentation discusses the basic definitions of extractables and leachables, including details from a case study done using prefilled syringes and a second using a single-use bag.
This presentation demonstrates that in vitro, cell-based assays is an indispensable tool to quantify the biological activities, and to support the potency tests, for bio therapeutics.
Where sterility will be claimed, regulatory agencies worldwide require that the integrity of sterilizing-grade filter(s) is verified before and after use to ensure filter performance. This webinar highlights best practices and key considerations for performing filter integrity tests to give you a better understanding of how to design a robust integrity test operation in your own facility.
Understanding the source, options for control, and potential impact of bioburden throughout downstream biopharmaceutical processes is beneficial to process developers, production operators and pharmaceutical microbiologists. Process designs that reduce the risks of bioburden contamination will decrease process related failures and the resulting painful, time-consuming investigations.
|
|
|
|
|
|
|
|
|